T1	p 92 114	stable COPD patients .
T2	p 129 144	COPD patients ,
T3	p 596 630	60 COPD patients underwent dyspnea
T4	p 642 669	( VAS score ) and pulmonary
T5	p 679 686	testing
T6	i 718 725	placebo
T7	i 735 746	indacaterol
T8	i 762 763	.
T9	i 1352 1367	bronchodilators
T10	o 371 385	hyperinflation
T11	o 388 400	gas trapping
T12	o 416 423	dyspnea
T13	o 644 653	VAS score
T14	o 789 800	?sRAW-based
T15	o 901 938	of intrathoracic gas volume ( ?ITGV )
T16	o 964 987	residual volume ( ?RV )
T17	o 1045 1049	?VAS
T18	o 1169 1218	of ?ITGV ( p=0.002 ) , ?RV ( p=0.023 ) , and ?VAS
T19	o 1504 1508	lung